. After sequencing 799 1-kilobase regulatory (H3K4me3) regions within these loci in 568 individuals, we observed accurate imputation for 89% of common variants. We defined credible sets of ≤ 5 causal variants at 5 rheumatoid arthritis and 10 type 1 diabetes loci. We identified potentially causal missense variants at DNASE1L3, PTPN22, SH2B3, and TYK2, and noncoding variants at MEG3, CD28-CTLA4, and IL2RA. We also identified potential candidate causal variants at SIRPG and TNFAIP3. Using functional assays, we confirmed allele-specific protein binding and differential enhancer activity for three variants: the CD28-CTLA4 rs117701653 SNP, MEG3 rs34552516 indel, and TNFAIP3 rs35926684 indel.
Rheumatoid arthritis is an autoimmune disease with citrullinated peptide reactivity where chronic inflammation leads to joint destruction 5 . Type 1 diabetes (T1D) arises through autoimmune reactivity to proinsulin 6 and glutamic acid decarboxylase 7 , leading to destruction of pancreatic β cells and loss of insulin production. Genome-wide association studies have identified 101 rheumatoid arthritis loci 3, 8 and 53 T1D loci 4 ; these alleles implicate CD4 + T-cell function in autoimmunity [9] [10] [11] . However, causal variants for most loci have yet to be defined. Pinpointing them will enable mechanistic investigation to identify the specific genes, regulatory structures, and genetic mechanisms central to autoimmunity.
Bayesian fine-mapping has been successfully applied to prioritize associated variants in complex diseases 1, [12] [13] [14] . We fine-mapped 76 autosomal non-major-histocompatibility-complex loci in rheumatoid arthritis (11, 475 cases, 15,870 controls) 3 and T1D (9,334 cases, 11,111 controls) (Supplementary Table 1 ) 4 , covering 46 and 49 loci with known rheumatoid arthritis and T1D associations, respectively (Supplementary Table 2 ). To enable accurate comprehensive imputation, we used individuals genotyped on ImmunoChip, with dense SNP coverage in selected autoimmune disease loci. Our sample size is smaller than the largest of previously published association analyses 4, 8 . However, Okada et al. 8 used imputed genotypes but did not define credible sets, and while Onengut-Gumuscu et al. 4 determined credible sets, they did not use imputation so their study included fewer than half of the variants assessed here. We fine-mapped rheumatoid arthritis and T1D together since potential causal variants for both diseases overlap functional elements in CD4 + T cells 11 . Since fine-mapping methods are highly sensitive to missing data, we benchmarked different imputation strategies. After sequencing 799 1-kilobase regulatory (H3K4me3) regions in 568 individuals within these loci, we observed that the 1000 Genomes cosmopolitan reference panel yielded the best results ( Fig. 1) , while indels and multi-allelic variants remain challenging to impute (Supplementary  Note, Supplementary Tables 3-7 , and Supplementary Figs. 1-4) .
After imputation, we calculated association statistics for 66,923 variants for rheumatoid arthritis and 66,942 variants for T1D (minor allele frequency (MAF) > 1%, imputation quality score (INFO) > 0.3; Hardy-Weinberg P > 10 ), mostly consistent with previous studies (Supplementary Note and Supplementary Table 8 ). Using approximate Bayesian fine-mapping, we assigned posterior probabilities and defined a 95% credible set for each locus 1, 2 . Seven loci were significantly associated with both diseases (PTPN22, AFF3, CD28-CTLA4, BACH2, RASGRP1, PTPN2, and TYK2). Rheumatoid arthritis and T1D variant effect sizes were positively correlated in 64% of the tested loci (Methods, Supplementary Table 9 , and Supplementary Fig. 5 ), suggesting shared signals. To prioritize possible shared causal variants, we analyzed a combined dataset (20, 787 rheumatoid arthritis or T1D cases, and 18,616 controls; Methods) and observed significant associations at 28 loci. Most (62%) associated variants in these loci were in linkage disequilibrium with the strongest associated variant in either rheumatoid arthritis or T1D (coefficient of determination (R 2 ) > 0.8; Supplementary Table 10 ). The combined analysis indicated a potential shared signal at the PRKCQ locus (Supplementary Note) that was not significant in rheumatoid arthritis or T1D alone. We did not identify additional significant loci. We did not observe residual population stratification by combining both datasets (Supplementary Note, Supplementary Table 11 , and Supplementary  Fig. 6 ). Multinomial Bayesian fine-mapping accounting for opposing effects 15 did not identify additional loci (Supplementary Note  and Supplementary Table 12 ). Because six out of seven shared loci had smaller credible sets in the combined analysis than for the individual disease analyses (Supplementary Note), we decided to use the combined analysis for those six loci.
We narrowed down the list of probable causal variants to ≤ 5 in 5 out of 20 significant rheumatoid arthritis loci and 10 out of 34 significant T1D loci. We subsequently limited the analysis to 9 (rheumatoid arthritis), 14 (T1D), and 11 (combined) loci with ≤ 10 variants in the credible sets (Fig. 2a,b and Supplementary Table 13) . Credible sets for these loci were not markedly altered when considering variants unique to the Haplotype Reference Consortium (HRC) reference panel ( Supplementary Fig. 7 and Supplementary  Table 14) . To systematically investigate candidate causal variants for both diseases, we selected those with a posterior probability of > 0.2 (Table 1) . We considered variants to be potentially causal if they: (1) were a missense coding variant; or (2) were in a region with evidence of enhancer activity, and demonstrated allele-specific binding in electrophoretic mobility shift assays (EMSAs) and allele-specific enhancer function in luciferase assays (Supplementary Table 15 ). Approximate Bayesian fine-mapping assumes a single causal variant per locus, although multiple independent causal variants may be present. Therefore, we applied conditional analysis, exhaustive testing of all variant pairs, FINEMAP 16 (which assumes multiple variants), and haplotype analysis for regions where there was evidence of a secondary effect (P < 1.9 × 10
−5
). We identified 42 variants at 20 loci with a posterior probability of > 0.2 (Table 1), including 5 missense variants (PTPN22, DNASE1L3,  SH2B3, TYK2 , and SIRPG), 3 indels (ANKRD55, TNFAIP3, and MEG3), and 34 noncoding SNP variants (PTPN22, IL10, IFIH1,  CD28-CTLA4, ANKRD55, BACH2, CCL21, IL2RA, INS, SH2B3,  Chr13, MEG3, CTSH, TYK2 , SIRPG, UBASH3A, and C1QTNF6). We observed a 16-fold posterior probability enrichment for missense variants. Potentially causal missense variants at PTPN22, SH2B3, and TYK2 are well described in the literature 4, [17] [18] [19] (Supplementary Note and Supplementary Figs. 8-10 ). We also noted potentially causal missense variants in DNASE1L3 and SIRPG.
DNASE1L3 encodes a nuclease that cleaves double-stranded DNA during apoptosis 20 . The 3p14 DNASE1L3 locus confers rheumatoid arthritis susceptibility without evidence of a T1D effect (P > 0.02; Supplementary Fig. 11 ). The reported 3 lead SNP rs35677470, encoding an p.Arg206Cys change in DNASE1L3, has a high posterior probability (P = 1.8 × 10 ; posterior probability = 0.82; Supplementary 
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; posterior probability = 0.24) for T1D ( Supplementary Fig. 12 and Supplementary Table 13 ). Conditional analysis using rs6043409 obviated any association signal in the locus (P > 2 × 10
−3
). p.Val263Ala is in the D3 domain 24 . While D3 has unknown function, homologous D1 and D2 immunoglobulin-like domains mediate interaction with CD47 ligands and SIRPG dimerization [25] [26] [27] . We observed linkage disequilibrium (R 2 > 0.8) with protein quantitative trait loci (QTL) and expression QTL (eQTL) SNPs (Supplementary Table 17 ), suggesting that p.Val263Ala might cause a SIRPG conformational change that alters stability, structure, or function. Since p.Val263Ala has unknown function, the two noncoding variants in the SIRPG credible set with comparable posterior probabilities and regulatory effects may potentially be causal. However, given the enrichment of missense variants in our data and elsewhere 28, 29 , we consider p.Val263Ala as the strongest candidate causal variant at this locus.
We identified noncoding alleles with allele-specific function at CTLA4-CD28, TNFAIP3, and MEG3 in regions with evidence of CD4 + T-cell enhancer function (Table 1) . We identified the rs61839660 variant at IL2RA with a high posterior probability (0.85), which was recently demonstrated to have allele-specific regulatory and cellular functions confirmed by CRISPR assays 30 . Detailed analyses of all other loci with ≤ 10 variants in the 95% credible set are presented in the Supplementary Note and Supplementary  Figs . 13-24. CD28 and CTLA4 are central to the regulation and differentiation of T cells 20 . The 2q33.2 CD28-CTLA4 locus is shared by rheumatoid arthritis and T1D 31 . In the combined analysis, a single variant had a high posterior probability (rs3087243; P = 1.4 × 10
−16
; posterior probability = 0.91) near CTLA4, which also has the largest posterior probability in T1D (P = 1.6 × 10
−15
; posterior probability = 0.48; Fig. 3a, Supplementary Fig. 25a , and Supplementary  Table 13 ), but not in rheumatoid arthritis (P = 1.6 × 10 −8
; posterior probability = 0.02). In contrast, rs117701653 near CD28 (R 2 = 0.03 with rs3087243) carried the highest posterior probability in rheumatoid arthritis (P = 3.5 × 10 ; posterior probability = 0.67). In conditional analysis on rs3087243, rs117701653 demonstrated an independent effect (P = 4.0 × 10 −8
; Fig. 3a and Supplementary Table 16 ). The FINEMAP 16 program identified the rs117701653 + rs3087243 pair as having the highest posterior probability (0.05; Supplementary  Table 18) , consistent with an analysis where we tested all SNP pairs exhaustively in rheumatoid arthritis ( Fig. 3b and Supplementary  Fig. 25b ). Haplotype analysis demonstrated independent protective effects of rs3087243-A and rs117701653-C alleles in rheumatoid arthritis and T1D (Fig. 3c) , suggesting that rs117701653 might similarly influence T1D risk (P = 0.03 in the conditional haplotype analysis). A previous association study identified rs1980422 as the variant with the strongest association in the CD28 region 8 (R 2 = 0.02 with rs117701653 and R 2 = 0.04 with rs3087243). Haplotype analysis indicated that rs1980422 imperfectly tags high-frequency haplotypes defined by rs3087243 and rs117701653 ( Supplementary  Fig. 25c 
Letters
NATUre GeNeTicS We declare variants at these loci as potentially causal when they are coding and have a posterior probability (PP) of > 0.2, or when they are noncoding, have a PP of > 0.2, and have functional evidence from the EMSA and luciferase assays. Logistic regression odds ratio (OR) values are from a two-sided χ 2 test (combined, n = 39,403; T1D, n = 20,445; rheumatoid arthritis (RA), n = 27,345).
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We observed allele-specific protein binding and enhancer activity for rs117701653, but not rs3087243 (Fig. 3d) . The rs117701653-C allele showed higher specific binding than the A allele in Jurkat T-cell nuclear extracts by EMSA ( Supplementary Fig. 25d ) and conferred higher luciferase expression (P = 0.0017; Fig. 3e ). The binding is lineage specific: it was absent in THP-1 monocytic cells ( Supplementary Fig. 25d ). We observed peak overlap in an assay for transposase-accessible chromatin sequencing (ATAC-Seq) for rs117701653 in CD4 + T cells (Supplementary Table 25 ) and a subtle increase in luciferase expression with the C allele after anti-CD3/ CD28 cell stimulation (P = 0.02; Supplementary Fig. 25e ), suggesting that binding may be stimulation dependent. While the rheumatoid arthritis credible set variant rs55686954 (R 2 = 0.91 with rs117701653, posterior probability = 0.27) showed allele-specific protein binding, it had no evidence of allele-specific enhancer function ( Supplementary Fig. 25d ,e). Promoter-capture Hi-C assays 32 demonstrated genomic contacts between the rs117701653 region and the CTLA4 promoter and a region downstream of RAPH1 ( Supplementary Fig. 26 ), suggesting that, despite its proximity to CD28, the allele may influence CTLA4 or RAPH1 gene regulation.
MEG3 is a noncoding RNA tumor suppressor gene whose transcript binds p53 (ref.
33
). Paternal alleles carry greater risk 34 in this 14q32.2 T1D locus. It shows no association to rheumatoid arthritis (P > 0.04). Two variants with > 0.2 probabilities in the credible set were the rs34552516 indel (P = 1.1 × 10
; posterior probability = 0.42) and rs56994090 intronic variant (P = 1.1 × 10
; posterior probability = 0.44; linkage disequilibrium with rs34552516, R 2 = 0.99; Fig. 4a , Supplementary Fig. 27a , and Supplementary  Table 12 ). While we observed no evidence of independent variants conditioning on rs34552516 (P > 0.04; Supplementary rs55686954  rs1980421  rs1980422  rs147080309  rs7422494  rs7426056  rs7588874  rs67895606  rs117701653  rs4673266  rs231389  rs13429019  rs62184035  rs13033315  rs11393378  rs3087243  rs1427676  rs11571302  rs7565213  rs231729  rs11571297  rs79570815  rs34029700  rs35184056  rs6435212   rs55686954  rs1980421  rs1980422  rs147080309  rs7422494  rs7426056  rs7588874  rs67895606  rs117701653  rs4673266  rs231389  rs13429019  rs62184035  rs13033315  rs11393378  rs3087243  rs1427676  rs11571302  rs7565213  rs231729  rs11571297  rs79570815  rs34029700  rs35184056 Conditioning on rs30872043 identifies rs117701653 as an independent association. Logistic regression − log 10 [P] values are from a two-sided χ 2 test (n = 39,403). b, An exhaustive pairwise analysis for rheumatoid arthritis shows that the rs3087243 + rs117701653 pair has the strongest association. Logistic regression − log 10 [P] values are from a two-sided χ 2 test (n = 27,345). c, Haplotype analysis using rs30872043 and rs117701653, with the AG haplotype as a reference. The C allele of rs117701653 shows the largest decrease in risk for rheumatoid arthritis (RA), and the A allele of rs30872043 shows the largest decrease in risk for T1D. Logistic regression odds ratios (dots) and 95% confidence intervals (bars) are from a two-sided χ 2 test (combined n = 39,403; T1D n = 20,445; RA n = 27,345). d, EMSA with Jurkat nuclear extract using probes containing rs117701653 and rs3087243. A representative blot of three independent experiments is shown. e, Luciferase assay in Jurkat T cells transfected with pGL3 plasmids containing rs117701653. RLUs are normalized to cells transfected with the empty plasmid (pGL3). Dots represent independent experiments, each of which was performed in duplicate. Means ± s.d. and two-tailed P values of the grouped comparisons (unpaired t-test) are shown.
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NATUre GeNeTicS FINEMAP analysis could not exclude the possibility of a secondary association (Supplementary Table 18 and Supplementary Note). Both MEG3 variants overlap DNAse-I hypersensitive sites (DHS) and H3K4me3 regions in multiple cell types (Supplementary Tables  20 and 21 ), but do not overlap ATAC-Seq peaks after stimulation (Supplementary Table 25 ) and are not in high linkage disequilibrium (R 2 > 0.8) with QTL SNPs. We observed that the rs34552516-TC allele demonstrated specific Jurkat cell nuclear extract binding (Fig. 4b) and increased luciferase activity compared with empty vector (P = 0.01) and the T allele (P < 0.05; Fig. 5c ). We observed no specific binding in THP-1 cells ( Supplementary Fig. 27b ), indicating cell-type specificity. In contrast, we observed no allele-specific binding for rs56994090 (Fig. 4b) . The region harboring rs34552516 in promoter-capture Hi-C data 32 showed contacts to DIO3 and RP11-1029J19 promoters ( Supplementary Fig. 26 ), suggesting multiple downstream genes. We favor rs34552516 as potentially causal based on our functional evidence, but acknowledge that these assays are limited and cannot exclude rs56994090 function that may occur in other unexamined cellular contexts.
The 6q23.3 TNFAIP3 gene encodes A20, which inhibits nuclear factor-κ B signaling and prevents apoptosis 20 . It is associated with multiple autoimmune diseases [35] [36] [37] [38] [39] [40] [41] , including rheumatoid arthritis, but not T1D (P > 2.3 × 10
−4
). The indel rs35926684 carries the highest posterior probability (P = 6.5 × 10 −12
; posterior probability = 0.24; Fig. 5a , Supplementary Table 13 , and Supplementary Fig. 28a ) of 9 variants in the credible set and is in linkage disequilibrium with the previously identified SNPs rs17264332 (R 2 = 0.86) 8 and rs6920220 (R 2 = 0.88) 3 . Conditional analysis identified independent association at rs58721818 (P = 3.6 × 10 Table 16 ). A previous study 3 identified secondary signals at rs5029937 (linked to rs58721818; R 2 = 0.84) and rs13207033. Exhaustive pairwise analysis demonstrated comparable association for the rs35926684 + rs58721818 pair (− log 10 [P] = 13.95) and the most strongly associated rs6920220 + rs58721818 pair (− log 10 [P] = 14.21; Fig. 5b and Supplementary Fig. 28b ). Haplotypes with the rs35926684-G allele increased rheumatoid arthritis risk, even in absence of the highly linked rs6920220-A risk allele (that is, GGGC versus GAGC; Fig. 5c ), although this effect was not significant in conditional haplotype analysis (P = 0.14). Consistent with our exhaustive pairwise search, FINEMAP identified the rs35926684 + rs58721818 combination as having the thirteenth highest posterior probability (Supplementary Table 18 ).
The rs35926684 indel alters binding motifs, overlaps enhancer marks and Encyclopedia of DNA Elements transcription factor binding site (TFBS) chromatin immunoprecipitation sequencing peaks in immune cell types (Supplementary Note and Supplementary  Tables 20, 21, and Table 17 ). EMSA identified stronger specific binding of Jurkat-cell nuclear extract for the rs35926684-GA allele than the G allele ( Fig. 5d and Supplementary Fig. 28c ). Luciferase assays demonstrated increased enhancer activity with the GA allele compared with the empty vector (P = 7 × 10 −4
) and G allele (P = 0.053; Fig. 5e ). We observed no specific binding in THP-1 cells, indicating cell-type specificity ( Supplementary Fig. 28c ). We observed no allele-specific binding for rs6920220 ( Supplementary Fig. 28c ) or the other four alleles in partial linkage disequilibrium with rs35926684 (posterior probability > 0.1), except for rs62432712. We did not observe allele-specific enhancer activity for rs62432712 (Supplementary Fig. 28d ). Hence, for this locus, we favor rs35926684 as the potentially causal variant since it has the best evidence of allele-specific activity. Nevertheless, the presence of multiple alleles in linkage disequilibrium (R 2 > 0.86) provides ambiguity at this locus. Interestingly, in promoter-capture Hi-C data, the rs35926684 region contacts the TNFAIP3 promoter 42 and the IL22RA and IFNGR1 promoters ( Supplementary Fig. 26 ) 32 , suggesting that multiple genes may be influenced by this rheumatoid arthritis risk allele.
Our study illustrates some challenges of fine-mapping. First, only a few loci had ≤ 10 plausible causal variants, and in even fewer was a   rs6933404  rs62432712  rs2327832  rs11314585  rs6927172  rs11757201  rs17264332  rs71718397  rs9494883  rs5029949  rs3834310  rs9494892  rs9494893  rs7752903  rs9494894  rs148314165  rs200820567  rs7749323  rs9494895  rs6932056  rs61117627  rs17781283   rs6933404 (11, 475 cases, 15,870 controls). The variant with the strongest posterior probability in this locus is rs35926684, a G/GA indel. Conditional on rs35926684, we observe a significant secondary association with rs58721818. Logistic regression − log 10 [P] values are from a two-sided χ 2 test (n = 27,345). b, Exhaustive pairwise association analysis in rheumatoid arthritis indicates that there are 11 pairs with a lower P value than rs35926684 + rs58721818, although the top-associated pair (rs69220220 + rs58721818) has an equivalent P value − log 10 [P] = 13.95 versus 14.21. Logistic regression − log 10 [P] values are from a two-sided χ 2 test (n = 27,345). c, Haplotype analysis with rs35926684 + rs58721818 and previously reported variants rs6920220 and rs5029937 shows that rs35926684 and the previously reported top variant rs6920220 are often located on the same haplotype (GAGC), although a rare haplotype exists with only the alternative allele of rs35926684, which causes a similar increase in risk, but with a larger confidence interval. Logistic regression odds ratios (dots) and 95% confidence intervals (bars) are from a two-sided χ 2 test (n = 27,345). RA, rheumatoid arthritis d, EMSA with Jurkat nuclear extract using probes containing the G or GA allele of rs35926684. A representative blot of three independent experiments is shown. e, Luciferase assay in Jurkat T cells transfected with pGL3 plasmids containing rs35926684. RLUs are normalized to cells transfected with the empty plasmid (pGL3). Dots represent independent experiments, each of which was performed in duplicate. Means ± s.d. and two-tailed P values of comparisons (unpaired t-test) are shown.
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it possible to identify promising candidates. Nonetheless, identifying plausible candidates in even a few instances is valuable. Second, we identified multiple potentially causal variants that were indels. Indels are the most likely to be missed or poorly imputed by current imputation reference panels (Supplementary Note), although coverage could improve with more complete reference panels based on highdepth whole-genome sequencing data. Third, since most loci have many plausible variants with low posterior probabilities, strategies to accurately predict causal variation from functional annotations are critical. This will require more precise noncoding maps that define regulatory elements central to the functions of pathogenic cell types.
We used a posterior probability of > 0.2 to prioritize variants for functional follow-up, which allowed us to include variants that might have been excluded by fluctuations in calculated probabilities caused by quality control, genotyping error, imputation quality, and parameter choices. This threshold is relatively stringent (only 42 variants passed it in our entire study), and variants with a posterior probability of < 0.2 may also be worthy of further investigation. We focused on loci with ≤ 10 variants in the 95% credible set; 12 loci had > 10 variants in the 95% credible set and at least 1 variant with a posterior probability of > 0.2 (Supplementary Table 26 ). In the RASGRP1 and PRKQC credible sets, we observed a single variant with tenfold higher posterior probability than the remaining variants, but we did not investigate these loci in detail since they had weaker association and their credible set size suggests extensive linkage disequilibrium, making determination of the functional impact more difficult.
We used Jurkat T-cell lines for EMSA and luciferase assays since T cells are critical to the genetic etiology of rheumatoid arthritis and T1D. We acknowledge that, in vivo, many contexts may be relevant, some of which may not be captured by these assays. Consequently, many of the remaining variants with a posterior probability of > 0.2 are plausible candidates that cannot be ruled out. Furthermore, our study is limited in identifying causal molecular mechanisms and genes. First, variants may be linked to multiple genes. For example, the region harboring the rs117701653 variant shows chromatin contacts with the CTLA4 promoter and the RAPH1 gene. Second, only a limited number of prioritized variants were in linkage disequilibrium with different molecular QTLs. As such, the specific gene(s) accounting for disease susceptibility remain(s) to be determined. Despite these limitations, we believe that the combination of statistical evidence with functional follow-up is a powerful way to prioritize potentially causal variants. Defining cellular models that best represent the pathogenic cellular contexts is an essential component for this functional follow-up.
URLs. Bios eQTL browser, http://genenetwork.nl/biosqtlbrowser/; Roadmap Epigenomics datasets, http://www.roadmapepigenomics.org/; ChromHMM enhancers and promoters, http://egg2.wustl.edu/roadmap/web_portal/; 1000 Genomes reference panel, http://bochet.gcc.biostat.washington.edu/beagle/1000_ Genomes_phase3_v5a/; Haplotype Reference Consortium panel, http://www.haplotype-reference-consortium.org/.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-018-0216-7. . For rheumatoid arthritis, we used data for 11,475 cases and 15,870 controls from 6 different cohorts (from the UK, the Swedish Epidemiological Investigation of Reumatoid Arthritis, the USA, the Netherlands, Umeå (Sweden), and Spain) 3 . For T1D, we used data for 12,241 cases and 14,636 controls from 2 different cohorts 4 : the Type 1 Diabetes Genetics Consortium (T1DGC) family collection, and the UK Genetic Resource Investigating Diabetes (GRID), British 1958 Birth Cohort, and UK Blood Service collection. To include trios from the Type 1 Diabetes Genetics Consortium cohort in the case-control analysis, we generated pseudocontrol pairs for each affected individual using the untransmitted alleles from the parents of that individual. As a consequence, the final numbers of individuals for T1D were 9,334 cases and 11,111 controls (including 1,661 pseudocontrols). Genotype quality control was performed as described in the previously published studies. Additionally, we merged the genotype data for the different cohorts within T1D and rheumatoid arthritis using PLINK 43 , and converted genomic coordinates using the University of California, Santa Cruz liftOver tool 44 and the hg18ToHg19 chain file. Variants unable to liftOver were removed. We then replaced the variant identifiers using National Center for Biotechnology Information Database of Single Nucleotide Polymorphisms (dbSNP) build 138 45 . Finally, we removed variants with a MAF of < 0.5%.
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Imputation.
To assess the imputation strategy best suited for fine-mapping, we tested three reference panels: (1) the European subpopulation of 1000 Genomes (n = 503); (2) the cosmopolitan panel of 1000 Genomes (n = 2,504); and (3) the HRC version 1.1 reference panel (n = 32,611). We matched variants to each reference panel, removed variants absent in the reference panel, and aligned the strands of the remaining ImmunoChip genotypes. We extended the disease loci upstream and downstream by 1 Mb. We excluded variants when alleles could not be matched. For C/G and A/T variants, we removed the variant when the minor allele was unequal and the MAF was < 45%. For multi-allelic variants, we ensured that the allele encoding was identical to the reference panel variant. This resulted in a different number of input variants for each imputation strategy (Supplementary Table 6 ). We imputed genotypes into rheumatoid arthritis and T1D separately. We phased and imputed the 1000 Genomes reference panels using Beagle version 4.1 (22Apr16.1cf) 46 . To accommodate computational constraints of Beagle, we split the rheumatoid arthritis and T1D datasets into 30 batches, randomizing cases and controls between batches, while maintaining trio structure in the T1D dataset. Since the HRC version 1.1 reference panel genotype data are not publicly available, we evaluated different imputation servers and settings for the T1D dataset, to determine their effects on imputation output. On the Sanger Institute imputation server (date of access: 11 May 2016), we used prephasing with either EAGLE (version 2.3.4) 47 or SHAPEIT (version 2.r837) 48 , followed by imputation with PBWT (version 3.0) 49 . On the Michigan University server (date of access: 5 July 2016), we split the dataset into three batches and used prephasing with EAGLE 47 and imputation by MiniMac 50 . For rheumatoid arthritis, we performed HRC imputation on the Sanger imputation server using EAGLE prephasing followed by PBWT imputation. Finally, we locally performed 1000 Genomes imputation by first phasing with EAGLE, and subsequently imputing using PBWT. We then merged the imputed dosages and probabilities from each batch (if any) for each imputation reference panel and replaced the variant identifiers in the imputed output using National Center for Biotechnology Information dbSNP build 138. We replaced genotypes for variants genotyped on ImmunoChip with the original genotypes. Genotyped variants correlated with genotypes after imputation (R 2 > 0.99). Finally, we recalculated the imputation quality scores for each imputed variant in each dataset: we used the INFO score for biallelic variants and Beagle version 4.1 allelic-R 2 for multi-allelic variants.
Targeted sequencing. To test the accuracy of imputation, we sequenced 900 regions of 1,000 base pairs (bp) around H3K4me3 peak centers overlapping loci associated with either disease in 864 individuals: 384 unrelated rheumatoid arthritis and 480 T1D individuals (160 trios), of which 149 and 480 were on ImmunoChip, respectively. We generated 100-bp paired-end reads with the Illumina MiSeq platform. Sequencing was performed at The Feinstein Institute for Medical Research at Northwell Health, and at The Center for Public Health Genomics, at the University of Virginia. We used BWA-mem 51 (version 0.7.12) to align reads to the hg19 reference genome. We tagged and removed duplicate reads using Picard MarkDuplicates. We removed 101 regions where > 50% of the samples had < 20× coverage at > 80% of sequenced bases, and removed 86 samples having < 20× coverage at 90% of sequenced bases. We called genotypes using GATK version 3.4, following the recommended guidelines for using HaplotypeCaller 52 in a joint genotype-calling approach. To determine the impact of local alignment on indel calls, we also called variants using the UnifiedGenotyper present in GATK. We then set genotypes with < 10× coverage and genotype quality (QUAL) < 30 to missing, and excluded variants with > 5% missingness. We correlated called genotypes with ImmunoChip genotypes to identify and remove (when the coefficient of correlation (r) < 0.95) possible sample swaps and mismatched samples, resulting in 568 final samples (439 for T1D and 129 for rheumatoid arthritis). Finally, we selected variants with MAF > 1%, resulting in 1,862 variants within the 76 rheumatoid arthritis-and T1D-associated regions.
Combined dataset.
Before the association analysis, we merged the data for the rheumatoid arthritis and T1D dataset, imputed with the cosmopolitan reference panel of 1000 genomes. We identified shared controls between datasets by generating a list of linkage disequilibrium pruned variants from the ImmunoChip genotypes using PLINK 43 (using --indep-pairwise 1000 100 0.2) and then used this list to determine the genetic similarity (unified additive relationship) 53 between each pair of samples across both datasets. We considered sample pairs with a unified additive relationship of > 0.2 genetically related, and randomly selected one sample of the pair to be included. We considered the remaining sample pairs unrelated. We finally merged genotypes and imputation probabilities from the selected samples and recalculated the imputation INFO scores for the merged genotypes as described earlier.
Fine-mapping and statistical analysis. We limited our association analysis to variants with an overall MAF of > 1%, a Hardy-Weinberg P value of > 10 −5 in controls, and an overall INFO score > 0.3. The Hardy-Weinberg P value was calculated using an exact test for biallelic variants and a Pearson's chi-squared test for multi-allelic variants. We then split multi-allelic variants, creating a single variant for each alternative allele. To test each variant for association with disease, we used logistic regression, assuming a log-linear relation between the number of alternative alleles and case-control status. In the rheumatoid arthritis dataset, the null model included the first ten principal components calculated over the genotype covariance matrix, as described previously 3 , and five additional covariates indicating the cohort. For T1D, we included 12 regional indicator variables in the null model, as described previously 4 , and an additional variable indicating the cohort. For the joint analysis, the null model included all covariates for the T1D and rheumatoid arthritis datasets and an additional covariate indicating the sample originating dataset. We recoded the imputation probabilities to a dosage value ranging between 0 and 2 (that is P(AB) + 2 × P(BB)). Finally, we calculated the P value for the association as the difference in deviance between the null model and alternative model containing the imputation probabilities, which follows a chi-squared distribution with one degree of freedom. We corrected for multiple testing using a study-wide Bonferroni threshold using the maximum number of tests across datasets (P < 7.5 × 10 −5 ~ 0.05/67,156). To test whether our model was properly adjusting for population stratification when performing the combined analysis, we also evaluated using the first 20 principal components as covariates. We obtained principal components with the PLINK 43 -pca command using the non-imputed and pruned combined ImmunoChip genotypes. By also including a covariate indicating the source dataset of each individual, we accounted for any residual technical differences caused by rheumatoid arthritis and T1D samples being genotyped and imputed independently.
Definition of credible sets. To define potentially causal variants for each locus, we calculated posterior probabilities using the approximate Bayesian factor (ABF) 1, 2 under the assumption of a single causal variant per locus. This framework assumes that the association effect sizes follow a distribution of N(0,V) under H 0, with V being the squared standard error. Under H 1 , the framework assumes a distribution following N(0,V + W), where W is (ln[1.5]/1.96) 2 , reflecting the prior of observing an odds ratio of 1.5. The ABF for an observed effect size β is then calculated as the ratio of P(β|H 0 )/P(β|H A ). Using the sum of the ABF for all variants in the locus, we calculate the posterior probability (PP) for variant i as:
Following calculation of the posterior probability, we created credible sets by sorting associations descending on the basis of their posterior probability and including associations such that the sum of posterior probability was > 0.95.
Detecting secondary associations.
To determine the presence of multiple independent effects, we performed conditional analyses using logistic regression. For each locus with a significant association, we included the top-associated variant as a covariate in the null and alternative models and repeated the association analysis for that locus. We considered secondary associations significant when P < 1.9 × 10 −5 (Bonferroni correction for maximum number of variants in significant loci: 0.05/2,704). We then performed exhaustive pairwise association analyses to test whether the primary and secondary associations together provided the strongest pairwise association signal given all possible pairs of variants in the locus. We calculated a P value using the difference in deviance between the null and alternative models, following a chi-squared distribution with two degrees of freedom.
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Finally, for loci with two or more independent associations, we assessed whether the risk alleles for the associated variants were located on the same haplotypes. We derived haplotypes from the phased imputation output (for example, four haplotypes for two independent variants). We removed all haplotypes with a frequency of < 1% and individuals having those haplotypes, and used the haplotype with the highest frequency as a reference. We then used logistic regression to test remaining haplotypes for association, assuming a log-linear relationship between the number of haplotype copies and disease status. To correct for population differences, our null model included covariates as described above.
We also performed fine-mapping using FINEMAP version 1.1 16 , which allows multiple independent associations per locus. As input, we used the summary statistics for the individual disease association analyses and genotype correlation matrices as linkage disequilibrium estimates. Finally, we assessed whether opposite effects between rheumatoid arthritis and T1D may cause lower power in the combined analysis by applying Trinculo version 0.96 15 -a method that implements multinomial logistic regression. As covariates for this analysis, we used the 20 principal components and indicator variable described above, to prevent multicollinearity.
Overlap with eQTLs, H3K4me3 peaks, DNAse-I hypersensitive sites, enhancers, and motifs. To provide functional annotation for the identified variants, we assessed overlap with eQTLs, H3K4me3 peaks, DNAse-I hypersensitive sites, promoters, and enhancers. We used eQTLs from an RNA sequencing-based eQTL meta-analysis of 2,116 whole blood samples 54 , a study assessing eQTLs in CD4 + T cells from 461 individuals 55 , a study assessing eQTLs in CD4 + and CD8 + cells from 313 individuals 56 , and tissue-specific eQTLs from the Genotype-Tissue Expression (GTEx) project 57 . We also included molecular QTLs, such as histone QTLs, methylation QTLs, and protein QTLs 56, 58 . For each variant in a credible set, we considered a QTL to be overlapping when it was in high linkage disequilibrium (R 2 > 0.8) with the top QTL for a given gene, methylation probe, histone mark, or protein. For calculation of linkage disequilibrium, we used the European subpopulation of 1000 Genomes.
For further annotation, we determined the overlap of variants with a posterior probability of > 0.2 with H3K4me3 peaks, DNAse-I peaks, and ChromHMM 59 genome segmentations from 12 imputed epigenetic marks from the Roadmap Epigenomics Consortium 60 , consisting of 127 consolidated epigenomes from different cell types. Furthermore, we determined whether candidate causal variants affected protein-binding motifs or transcription factor binding sites using HaploReg 61 . Finally, we determined overlap with TFBSs using Encyclopedia of DNA Elements project transcription factor chromatin immunoprecipitation sequencing 62 and determined whether these variants overlapped conserved TFBS motifs by defining a 40-bp region around each variant, and using the Homer 63 software to test all known motifs in vertebrates.
ATAC-Seq time series.
We applied ATAC-Seq 64 to measure chromatin accessibility in a time series after stimulation. We used a leukopak (30 ml whole blood) from a healthy anonymous donor to isolate peripheral blood mononuclear cells using Ficoll tubes, which were stored in 500 µ l aliquots of 100 × 10 6 cells in liquid nitrogen. Cells were subsequently thawed and stained with anti-biotin microbeads to magnetically select CD4 + Tmem cells. Cells were resuspended and transferred to 24-well plates in 3 ml aliquots of 6 × 10 6 cells and stimulated using Dynabeads (Human T-Activator CD3/CD28 for T Cell Expansion and Activation; Life Technologies) in a ratio of two cells per bead. Samples of 100,000 cells were taken at 0, 1, 2, 4, 8, 12, 24, and 48 h after stimulation. Nucleosome isolation and ATAC-Seq open chromatin sequencing were performed as described earlier 64 . Sequenced reads were mapped to the hg19 reference genome using BWA-mem. Reads mapping to the mitochondrial genome or to multiple genomic locations, and duplicate reads (labeled by Picard MarkDuplicates (version 1.128)) were removed, and reads were shifted + 4 and − 5 bp for the reverse and forward strands, respectively. Enrichment for open chromatin was determined by calling peaks using MACS version 2.1.0 (ref. 65 ) (default settings). EMSAs. EMSAs were performed using the LightShift Chemiluminiscent EMSA Kit (Thermo Scientific). Single-stranded oligonucleotides corresponding to 30-32 nucleotide fragments of the human genome with the SNP of interest in the middle were purchased from Integrated DNA Technologies (Supplementary  Table 27 ) and biotinylated using the Biotin 3´ End DNA Labeling Kit (Thermo Scientific). Double-stranded oligonucleotides were generated by mixing equal amounts of biotin-labeled (for the probe) or unlabeled (for the competitor) complementary oligonucleotides and incubated for 5 min at 95 °C and then 1 h at room temperature.
Nuclear extract from Jurkat and THP-1 cells was obtained using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific). Protein extracts were dialyzed using a dialysis membrane with a molecular weight cutoff of 12-14 kDa (Spectrum Spectra) against 1 l of dialysis buffer (10 mM Tris pH 7.5, 50 mM KCl, 200 mM NaCl, 1 mM dithiothreitol, 1 mM phenylmethane sulfonyl fluoride, and 10% glycerol) for 16 h at 4 °C with slow stirring. Protein inhibitor cocktail (Sigma) was added to a final concentration of 2.5× . The protein concentration was measured using the Pierce BCA Protein Assay Kit (Thermo Scientific).
The standard binding reaction contained 2 µ l of 10× Binding Buffer (100 mM Tris pH 7.5, 500 mM KCl and 10 mM dithiothreitol), 2.5% glycerol, 5 mM MgCl 2 , 0.05% NP40, 50 ng Poly(dI:dC), 20 fmol biotin-labeled probe, and 16 µ g nuclear extract in a final volume of 20 µ l. For competition experiments, a 200-fold molar excess (4 pmol) of unlabeled probe was added. Variations to these conditions are indicated in the corresponding figure (Supplementary Figures 25D, 27B, and 28C) .
Binding reactions were incubated at room temperature for 30 min and loaded onto a 6% polyacrylamide 0.5× TBE Gel. After sample electrophoresis and transfer to a nylon membrane, transferred DNA was crosslinked for 10 min, and the biotinylated probes were detected by chemiluminescence followed by film exposure. Original films are presented in Supplementary Fig. 29 .
Luciferase reporter assay. The double-stranded oligonucleotide containing the SNP of interest (obtained as described above) was cloned downstream from the luciferase gene in the luciferase reporter vector pGL3 promoter (Promega). Unlabeled double-stranded oligonucleotides containing the corresponding SNPs were amplified with specific primers containing the BamHI restriction site obtained from Integrated DNA Technologies (Supplementary Table 28 ). The PCR was carried out in 50 μ l reaction volume under the following program: 94 °C for 3 min; 10 cycles at 94 °C for 30 s, 60 °C for 40 s, and 68 °C for 30 s; 15 cycles at 94 °C for 30 s, 60 °C for 40 s, and 68 °C for 30 s; and 72 °C for 10 min (AccuPrime Taq; Invitrogen). Both the PCR products and pGL3 promoter vector were digested with BamHI (New England Biolabs) for 1 h at 37 °C, and linearized vector was then dephosphorylated for 30 min at 37 °C with the Quick Dephosphorylation kit (New England Biolabs). Digestion products were purified with the QIAquick Gel Extraction Kit (Qiagen) from 1.2% agarose gels. Ligation of SNP-containing fragments into the pGL3 promoter plasmid was performed in a ratio of 1:50 (vector:insert) with T4 DNA ligase (New England Biolabs) at 16 °C overnight and transformed into JM109 competent cells (Promega). Plasmids from independent colonies were isolated using a Wizard Plus SV Minipreps DNA purification system and sequenced using RV primer 4 (Promega), selecting those harboring the SNPconstruct cloned 'in sense' in the pGL3 promoter vector for further HighPure plasmid isolation (Invitrogen).
At least three independent transfection experiments for each construct were performed, each in duplicate. 2 × 10 4 Jurkat cells in 0.1 ml of complete RPMI were transfected with 0.8 µ g of pGL3-Promoter vector along with 0.2 µ g of pRL-TK Renilla luciferase vector (Promega) using 1.5 µ l of Lipofectamine LTX Reagent and 1 µ l of PLUS Reagent (both from Invitrogen) diluted in Opti-MEM (Gibco). After 16 h of transfection, luciferase activity was measured using the Dual-Glo Luciferase Assay System (Promega). Firefly luciferase activity was expressed as relative luciferase units (RLU) after correction for Renilla luciferase activity to adjust for transfection efficiency. Data were normalized to those cells transfected with empty pGL3-Promoter vector.
For the rs117701653 variant at the CD28-CTLA4 locus, we also investigated the luciferase signal under stimulatory conditions. We transfected Jurkat cells as described above, and 18 h after transfection, cells were left untreated or stimulated with α CD3/α CD28 (0.5 µ g α CD3 coated to the plate and 5 µ g ml −1 of soluble α CD28) or phytohemagglutinin (2 µ g ml −1 ). Luciferase activity was measured 6 h after stimulation. Four independent experiments were performed in duplicate. The results of individual assays are presented in Supplementary Table 29 .
Statistical analysis of functional studies. Luciferase activity levels were compared by unpaired two-sided t-test. Error bars represent s.d.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Code availability. Associated computer code for this manuscript can be found at the following GitHub repositories: https://github.com/immunogenomics/harmjan/ tree/master/FinemappingPaper and https://github.com/immunogenomics/ harmjan/tree/master/FinemappingTools.
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Summary statistics for all variants are available through the following GitHub repository: https://github.com/immunogenomics/harmjan/tree/master/RA-T1D-Finemap-SummaryStats. Genotype data have been previously published 3, 4 and are available from Rheumatoid Arthritis Consortium International and the Type 1 Diabetes Genetics Consortium upon request. The ATAC-Seq data discussed in this publication have been deposited in the Gene Expression Omnibus under accession number GSE116497. 
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